{"entity":{"id":"nct05377996","kind":"trial","name":"A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Emi-Le in triple-negative breast cancer, endometrial cancer, ovarian cancer and salivary gland cancers, run by Day One Biopharmaceuticals, Inc., now recruiting.","summary":"A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors is a phase 1/2 interventional study registered as NCT05377996 by Day One Biopharmaceuticals, Inc., with 360 participants planned, started 2022-08-15 and due to reach its primary completion in 2027-02. Interventions recorded: Emi-Le.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05377996","url":"https://clinicaltrials.gov/study/NCT05377996"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["tnbc","endometrial","ovarian","salivary-gland","mucoepidermoid-carcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["day-one-biopharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05377996","phase":"1/2","setting":"A Phase 1/2, First-in-human, Multicenter Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors","sponsor":"Day One Biopharmaceuticals, Inc.","participation":[{"nct":"NCT05377996","source":"https://clinicaltrials.gov/study/NCT05377996","fetchedAt":"2026-10-07T16:53:41.225Z","studySha256":"ea6cd32362cc53e2fb601ff05c7de462d9796a6d9c28ea580fe77c6bfbe791ab","overallStatus":"RECRUITING","lastUpdatePosted":"2026-06-29","leadSponsor":"Day One Biopharmaceuticals, Inc.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":360,"enrolmentType":"ESTIMATED","siteCount":26,"recruitingSiteCount":26,"countries":["United States"]}],"started":"2022-08-15","startedType":"actual","enrolled":360,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05377996/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"mucoepidermoid-carcinoma","kind":"cancer","name":"Mucoepidermoid carcinoma","route":"/cancers/mucoepidermoid-carcinoma/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"salivary-gland","kind":"cancer","name":"Salivary gland cancers","route":"/cancers/salivary-gland/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"company":[{"id":"day-one-biopharmaceuticals","kind":"company","name":"Day One Biopharmaceuticals","route":"/companies/day-one-biopharmaceuticals/"}],"institution":[{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/"}]}}